IP Library Granted Patent US 7,709,270
Granted Patent B2
US 7,709,270 · App. 11/930,008 · Granted May 4, 2010

Vascular endothelial growth factor C (VEGF-C) protein diagnostic

Assignee: Vegenics Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,709,270
App. No.
11/930,008
Granted
May 4, 2010
Kind
B2
Abstract

Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.

Claims (24)

1. A diagnostic comprising:

(a) an antibody that specifically binds to a polypeptide that binds and stimulates phosphorylation of Flt4 receptor tyrosine kinase (Flt4), wherein the polypeptide has an amino acid sequence consisting of a portion of amino acids 103 to 282 of SEQ ID NO: 8, said polypeptide lacking all of amino acids of SEQ ID NO: 8 beyond position 282; and

(b) an agent for detecting said antibody in a sample.

2. The diagnostic of claim 1 wherein the agent is a paramagnetic or radioactive label.

3. The diagnostic of claim 2 wherein the label is attached to the antibody.

4. The diagnostic of claim 1 wherein the agent is packaged with the antibody as a kit.

5. A diagnostic comprising:

(a) an antibody that specifically binds to a polypeptide that binds and stimulates phosphorylation of Flt4 receptor tyrosine kinase (Flt4), wherein the polypeptide comprises a portion of SEQ ID NO: 8 effective to permit such binding, and wherein the polypeptide has an apparent molecular weight of approximately 23 kD as assessed by SDS-PAGE under reducing conditions; and

(b) an agent for detecting said antibody in a sample.

6. A diagnostic comprising:

(a) an antibody that specifically binds with a soluble polypeptide ligand of Flt4 receptor tyrosine kinase, wherein the soluble polypeptide ligand comprises a polypeptide encoded by the cDNA insert of plasmid pFlt4-L, having ATCC Accession No. 97231; wherein the polypeptide has a molecular weight of about 23 kD as assessed by SDS-PAGE under reducing conditions; and wherein binding of the antibody to the polypeptide ligand blocks activation of Flt-4 receptor tyrosine kinase by the polypeptide ligand; and

(b) an agent for detecting said antibody in a sample.

7. A diagnostic comprising:

(a) an antibody that specifically binds to a polypeptide that binds and stimulates phosphorylation of Flt4 receptor tyrosine kinase (Flt4), wherein the polypeptide has an amino acid sequence consisting of a portion of amino acids 103 to 282 of SEQ ID NO: 8, said polypeptide lacking all of amino acids of SEQ ID NO: 8 beyond position 282, wherein the polypeptide binds and stimulates phosphorylation of VEGFR-2, and wherein the antibody inhibits binding between the polypeptide and VEGFR-2; and

(b) an agent for detecting said antibody in a sample.

8. A diagnostic comprising:

(a) an antibody that specifically binds to a polypeptide that binds and stimulates phosphorylation of Flt4 receptor tyrosine kinase (Flt4), wherein the polypeptide comprises a portion of SEQ ID NO: 8 effective to permit such binding, wherein the polypeptide has an apparent molecular weight of approximately 23 kD as assessed by SDS-PAGE under reducing conditions, wherein the polypeptide binds and stimulates phosphorylation of VEGFR-2, and wherein the antibody inhibits binding between the polypeptide and VEGFR-2; and

(b) an agent for detecting said antibody in a sample.

9. A diagnostic comprising:

(a) antibody that specifically binds with a soluble polypeptide ligand of Flt4 receptor tyrosine kinase, wherein the soluble polypeptide ligand comprises a polypeptide encoded by the cDNA insert of plasmid pFlt4-L, having ATCC Accession No. 97231; wherein the polypeptide has an apparent molecular weight of approximately 23 kD as assessed by SDS-PAGE under reducing conditions, wherein the polypeptide binds and stimulates phosphorylation of VEGFR-2, and wherein the antibody inhibits binding between the polypeptide and VEGFR-2; and

(b) an agent for detecting said antibody in a sample.

10. A diagnostic comprising:

(a) an antibody which binds to a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 9; and

(b) an agent for detecting said antibody in a sample.

Continuity (10)
Continuation 1079248000 · Mar 3, 2004
Continuation 0953437600 · Mar 24, 2000
Continuation 0935570000
Continuation In Part 0879543000 · Feb 5, 1997
Continuation In Part PCTFI960042700 · Aug 1, 1996
Continuation In Part 0867157300 · Jun 28, 1996
Continuation In Part 0860113200 · Feb 14, 1996
Continuation In Part 0858589500 · Jan 12, 1996
Continuation In Part 0851013300 · Aug 1, 1995
Related Publication 20080241152A1 · Oct 2, 2008